BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX)

Historical Holders from Q1 2014 to Q3 2025

Symbol
BCRX on Nasdaq
Type / Class
Equity / Common Stock, $0.01 par value per share
Shares outstanding
210M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
194M
Holdings value
$1.47B
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
280
Number of buys
128
Number of sells
-145
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.4% $144M 17.5M BlackRock, Inc. 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 7.3% $116M 15.3M RA Capital Management, L.P. 04 Nov 2025
Flynn James E 5.8% $103M 12.2M Deerfield Mgmt, L.P. 12 Sep 2025
Avoro Capital Advisors LLC 4.2% $71.5M 8.7M Avoro Capital Advisors LLC 31 Mar 2025

Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 194M $1.47B -$36.1M $7.59 280
2025 Q2 197M $1.77B +$203M $8.96 292
2025 Q1 174M $1.31B +$63.4M $7.50 273
2024 Q4 168M $1.26B -$40.4M $7.52 256
2024 Q3 173M $1.32B -$13.5M $7.60 255
2024 Q2 174M $1.08B -$26.2M $6.18 238
2024 Q1 180M $914M +$14.5M $5.08 235
2023 Q4 177M $1.06B -$13.9M $5.99 234
2023 Q3 176M $1.24B +$20.8M $7.08 229
2023 Q2 174M $1.23B +$15.8M $7.04 233
2023 Q1 171M $1.42B +$99M $8.34 237
2022 Q4 158M $1.81B +$89.1M $11.48 225
2022 Q3 149M $1.88B -$39.5M $12.60 218
2022 Q2 152M $1.61B +$202M $10.58 207
2022 Q1 128M $2.07B +$162M $16.26 219
2021 Q4 118M $1.62B +$189M $13.85 197
2021 Q3 103M $1.48B -$23.7M $14.37 191
2021 Q2 105M $1.65B +$25.6M $15.81 190
2021 Q1 105M $1.06B -$142M $10.17 183
2020 Q4 121M $898M -$43.6M $7.45 172
2020 Q3 128M $438M -$23.5M $3.44 150
2020 Q2 133M $635M +$96.6M $4.76 160
2020 Q1 123M $245M -$37.9M $2.00 127
2019 Q4 137M $473M +$126M $3.45 131
2019 Q3 98.7M $283M -$6.97M $2.87 110
2019 Q2 100M $380M -$87.9M $3.79 112
2019 Q1 101M $826M +$1.49M $8.14 129
2018 Q4 101M $817M +$8.89M $8.07 118
2018 Q3 100M $764M +$73.7M $7.63 110
2018 Q2 87.5M $501M -$8.81M $5.73 98
2018 Q1 89.1M $425M -$6.63M $4.77 98
2017 Q4 90.3M $443M +$30.2M $4.91 111
2017 Q3 83.7M $439M +$76.3M $5.24 118
2017 Q2 69.1M $384M +$3.63M $5.56 112
2017 Q1 67.6M $568M +$140M $8.40 114
2016 Q4 58.4M $370M +$11.8M $6.33 107
2016 Q3 56.6M $249M +$23.4M $4.41 98
2016 Q2 51.8M $147M -$10.6M $2.84 91
2016 Q1 55.5M $157M -$57.9M $2.83 103
2015 Q4 63M $650M -$21.2M $10.32 116
2015 Q3 65M $740M +$18.2M $11.40 123
2015 Q2 63M $940M -$26.3M $14.93 121
2015 Q1 64.9M $586M +$36.7M $9.03 96
2014 Q4 60.8M $740M +$22.5M $12.16 90
2014 Q3 56.7M $554M +$30.6M $9.78 101
2014 Q2 53.1M $677M +$131M $12.75 100
2014 Q1 43.5M $460M +$93.2M $10.58 86